Trial Profile

Phase 1 proof-of-concept investigator-initiated trial of COYA 301 in Alzheimer's disease (AD) patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COYA-301 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Proof of concept

Most Recent Events

06 Feb 2025 Results published in the Coya Therapeutics Media Release.
20 Jun 2024 According to a Coya media release, company expands sponsored research collaboration with Houston Methodist Research Institute along with funding from the Johnson Center for Cellular Therapeutics to advance regulatory T cell exosome platform into the clinic.
16 Jan 2024 According to a Coya Therapeutics Media Release, topline data from this study anticipated in second half of 2024 (H2 2024).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com